# A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)

Source: https://onco.cc/trials/nct07302347/  
OnCo record `nct07302347` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab in merkel cell carcinoma and non-Hodgkin lymphoma, run by Merck Sharp & Dohme LLC, now recruiting.

## Summary

A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21) is a phase 1/2 interventional study registered as NCT07302347 by Merck Sharp & Dohme LLC, with 20 participants planned, started 2026-06-23 and due to reach its primary completion in 2029-03-30. Interventions recorded: Pembrolizumab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07302347
- Phase: 1/2
- Setting: A Phase I/II Study of Pembrolizumab (MK-3475) in Japanese Pediatric Participants With Specific Solid Tumors or Lymphomas, or in Japanese Adult Participants With Advanced Merkel Cell Carcinoma (KEYNOTE-G21)
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT07302347: https://clinicaltrials.gov/study/NCT07302347

## Connected records

- cancers: [Merkel cell carcinoma](https://onco.cc/cancers/merkel-cell-carcinoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct07302347.json